Demonstrating a Successful CAR-T Commercialisation Partnership with a Clinical Centre
The story of the UPenn – Novartis alliance and its impact on the CAR-T landscape
Dr Nicole Aqui from UPenn tells the story of the UPenn – Novartis alliance and its impact on the CAR-T landscape
Nicole does not have an MBA
Nicole is not an expert in contract negotiations
Dr Aqui caveats her presentations with some disclosures that we are not the kind we might be used to seeing! She is a medical doctor and in this 14-minute presentation gives you a unique perspective on the UPenn-Novartis alliance that began in 2012 and the impact it had on the CAR-T landscape.
The alliance ended in September 2019, but the result has been staggering. Not only was the first CAR-T therapy, Kymriah, commercialised but in Philadelphia alone over 30 new companies have been formed, over 3,000 jobs created and $1bn has been invested in cell and gene therapies.
Both parties have now entered a new, more focused, limited agreement for the development of CAR-Ts, so what lessons have been learned? Here’s Nicole’s summary:
- Academic-industry partnerships can move therapy forward at a faster rate than either party can do alone
- Partnerships should not be too broad
- Rights to IP and technology must be clearly aligned